Skip to content
thispeptide

RxPepsDirect

A $39 visit per order buys the prescription, and a Texas compounding pharmacy bills each vial at its listed price. The medical director and lead prescriber are named with NPI numbers; the pharmacy is not named.

Review by Leah Garner, clinical-evidence editor · Updated October 2026

The short version

RxPepsDirect is open about who signs the prescription and what each vial holds. It names its medical director and lead nurse practitioner, prints a dose and schedule on every product page, and publishes a sterility and endotoxin report for each batch. It does not name the pharmacy that compounds the drugs. Care after the order runs through dashboard messages, not scheduled visits.

Disclosure: This Peptide is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. How we make money.

Lowest listed: Glutathione injection, from $20 per vial

28 states plus DC

Visit RxPepsDirect →

RxPepsDirect is a cash-pay telehealth practice run by Peptide RX LLC, founded in 2026 by Marcus Hansen. It charges a flat $39 medical visit per order, and one order can hold up to three different peptides. A licensed 503A compounding pharmacy in Texas then bills you directly for the medication. The catalog lists more than 65 formulations across weight loss, growth hormone, recovery, longevity, sexual health and skin. Many of them, such as BPC-157, MOTS-c and the multi-peptide blends, fall outside what this site covers.

What RxPepsDirect prescribes, by goal

Weight

  • SemaglutideFDA-approved
    • Injection (compounded)From $25/mo$79 a month with the required consult and shipping, our total
  • TirzepatideFDA-approved
    • Injection (compounded)From $45/mo$99 a month with the required consult and shipping, our total

Compounded semaglutide comes mixed with vitamin B12, starting at $25 for a 1.2 mg vial dosed at 0.15 mg twice weekly. The printed ladder moves up one vial a month, reaching $108.64 for an 11.2 mg vial at month six. Compounded tirzepatide with B12 starts at $45 for 12 mg, at 1.5 mg twice weekly, and reaches $247.50 by month six. The tirzepatide FAQ notes that this twice-weekly split differs from the once-weekly brand schedule. Every vial after the starter needs proof of active care, such as a current prescription, chart note or recent lab result. Versions made with glycine instead of B12 start at $175 and $225.

Sexual health

  • PT-141 (bremelanotide)FDA-approved
    • Injection (compounded)From $75 per vial
    • Nasal spray (compounded)From $99 per kit

PT-141 injection is $75 for a 10 mg vial, starting at 0.4 mg about 45 minutes before sex. Your provider may raise it to 1 mg, with 1.75 mg as the stated maximum. PT-141 nasal spray is $99 for a 3 mL bottle, at 2.5 mg per spray in each nostril. Both pages allow at most eight doses a month across the two forms, at least 24 hours apart.

Longevity

  • GlutathioneLegal to compound
    • Injection (compounded)From $20 per vial
  • NAD+Legal to compound
    • Injection (compounded)From $100 per vial
    • Nasal spray (compounded)From $120 per kit

NAD+ injection is $100 for a 1,000 mg vial, taken as 50 mg three times a week; the page says one vial lasts about 46 days. NAD+ nasal spray is $120 for a 15 mL bottle at 10 mg per spray, one spray in each nostril daily. Glutathione is listed at $20 for 2,000 mg, taken as 100 mg up to five times a week. It is back-ordered, and new orders are paused with no restock date.

Recovery

  • SermorelinLegal to compound
    • Injection (compounded)From $80 per vial
  • GHK-CuLegal to compound
    • Topical (compounded)From $100 per kit

Sermorelin is $80 for a 15 mg vial, taken as 0.6 mg each evening from Monday to Friday. At that schedule one vial holds 25 doses, about five weeks. GHK-Cu is sold here as a 1% scalp solution at $100 for a 30 mL bottle, applied 1 mL a day for 30 days.

Sleep

  • SermorelinLegal to compound
    • Injection (compounded)From $80 per vial

Sermorelin's page lists sleep quality among its aims and times the dose for the evening, to match the body's own night-time growth hormone release. The FAQ says sleep, recovery and body composition are the day-to-day signals you and your clinician track.

Each “From” figure is the seller’s own starting price, in the unit the seller states. Where a required fee or a package length changes what one month costs, the smaller line under it is our arithmetic, not a figure the seller prints. Compounded preparations are not FDA-approved.

Who prescribes

A licensed clinician

The site names its clinicians and lists a federal NPI number for each, so a reader can check them in the national registry. Dr. Jonathan Snipes, MD, is the medical director. The FAQ says he practices through PWS-TX PLLC and supervises the nurse practitioner and physician assistant team. Kim Callender, FNP-BC, is named as lead prescriber, the clinician who signs the prescriptions you fill. The About page says the nurse practitioners and physician assistants are employed in-house rather than hired through a marketplace. The terms describe them as independently licensed, a phrase about licensure that does not settle employment. The pharmacy is described only as a licensed 503A compounding pharmacy in Texas. The quality page adds that it holds a sterile-compounding license and passed its latest state inspection. Its name is not given on any page.

You choose up to three peptides, pay the $39 at checkout, and answer a short adaptive health questionnaire. The telehealth consent says a licensed provider reviews it asynchronously, usually within 24 hours. A live video visit is optional: 30 minutes with Dr. Snipes costs $149.99, with the $39 fee included. Once the prescription is signed, the pharmacy texts a payment link and ships by FedEx overnight in a cooled case. Injectables arrive already mixed, with syringes and alcohol swabs. Follow-up runs through dashboard messages, and the FAQ says providers answer clinical questions within one business day. Each refill is a new $39 visit with a fresh provider review. The same peptide can be reordered 15 days after its last approval, or 21 days for semaglutide and tirzepatide.

Are labs required?

None ordered

No product requires lab work before a first order, and the tesamorelin page states that the practice does not order lab work. That page asks patients with diabetes to send a recent HbA1c or fasting glucose from their own doctor. For semaglutide and tirzepatide, a recent lab result is one of the documents accepted as proof of active care after the starter vial.

Ready to start with RxPepsDirect?

Lowest listed price: Glutathione injection, from $20 per vial. Confirm it on the seller’s own site.

Visit RxPepsDirect →

What it claims, and what it cites

The GLP-1 pages borrow their outcome figures from named trials of the brand-name drugs. The semaglutide FAQ cites STEP-1, at about 14.9% mean weight loss over 68 weeks. The tirzepatide FAQ cites SURMOUNT-1, at 15 to 22% over 72 weeks at therapeutic doses. Both trials tested once-weekly brand injections without B12, not the compounded twice-weekly vials sold here. The semaglutide page itself says the added B12 does not raise energy in people who are not deficient. The NAD+ page says levels fall by roughly half between ages 40 and 60, with no source beside the figure. The quality page publishes each batch's sterility and endotoxin report from Eagle Analytical Services, an independent Houston laboratory. It also says plainly that these reports include no purity assay, so no purity figure should be inferred. Potency was tested only on select batches. A comparison page written by the seller ranks its own catalog as the largest of eight peptide telehealth services.

On RxPepsDirect’s siteSource it gives
On RxPepsDirect’s site“The pivotal STEP-1 trial reported approximately 14.9 percent mean body weight loss at 68 weeks on semaglutide”Source it givesSTEP-1, by name; a trial of the brand-name drug
On RxPepsDirect’s site“The pivotal SURMOUNT-1 trial showed 15 to 22 percent mean body weight loss over 72 weeks at therapeutic doses”Source it givesSURMOUNT-1, by name; a trial of the brand-name drug
On RxPepsDirect’s site“Levels decline ~50% between ages 40-60 (NAD+)”Source it givesNone given
On RxPepsDirect’s site“Every batch, independently tested”Source it givesEagle Analytical Services sterility and endotoxin reports, published by lot
On RxPepsDirect’s site“Publishes the biggest selection (65-plus peptide and wellness formulations)”Source it givesIts own comparison of eight services

Sold by RxPepsDirect, not listed here

BPC-157
On no 503A list (removed from Category 2 in April 2026, never in Category 1). The FDA's compounding advisory committee voted 8–6 (one abstention) in July 2026 to favor listing it; the vote is a recommendation, not binding on the FDA, and pharmacies may not compound it until final rulemaking.
Ipamorelin
"Ipamorelin Acetate" is in 503B Category 2, bulk drug substances that raise significant safety risks (list updated March 21, 2025). It is named on no 503A list, so neither an outsourcing facility nor a 503A pharmacy has a listed route to it.
TB-500
On no FDA compounding list: absent from the 503A categories (updated May 14, 2026) and the 503B categories (updated March 21, 2025). FDA's compounding advisory committee voted 8-6 (one abstention) in July 2026 to favor listing it; the vote is a recommendation, not binding on the FDA, and pharmacies may not compound it until final rulemaking.
Tesamorelin
Approved only as Egrifta, for excess abdominal fat in adults with HIV-associated lipodystrophy. Its label says it is not indicated for weight loss. Egrifta became a biologic (BLA) on March 23, 2020, and FDA says compounded versions of these products do not qualify for the 503A or 503B compounding exemptions.
Oxytocin
We have not yet read its FDA status, so we list no seller for it.
AOD-9604
On no FDA compounding list. AOD-9604 appears in neither the 503A bulk drug substances categories (updated May 14, 2026) nor the 503B categories (updated March 21, 2025).
5-Amino-1MQ
On no FDA compounding list. 5-Amino-1MQ (5-amino-1-methylquinolinium) appears in neither the 503A bulk drug substances categories (updated May 14, 2026) nor the 503B categories (updated March 21, 2025).
MK-677
"Ibutamoren Mesylate" is in 503A Category 2, bulk drug substances that raise significant safety risks (list updated May 14, 2026), and in 503B Category 2 (updated March 21, 2025). Both lists bar it for the same stated reason.
KPV
On no FDA compounding list. KPV appears in neither the 503A bulk drug substances categories (updated May 14, 2026) nor the 503B categories (updated March 21, 2025). FDA's compounding advisory committee voted 8-6 (one abstention) in July 2026 to favor listing it; the vote is a recommendation, not binding on the FDA, and pharmacies may not compound it until final rulemaking.
Epitalon
On no FDA compounding list. Neither "Epitalon" nor "Epithalon" appears in the 503A bulk drug substances categories (updated May 14, 2026) or in the 503B categories (updated March 21, 2025).
MOTS-c
On no 503A list (not in Categories 1–3 of the May 14, 2026 update). The FDA's compounding advisory committee voted 7–5 (two abstentions) in July 2026 to favor listing it; the vote is a recommendation, not binding on the FDA, and pharmacies may not compound it until final rulemaking.
SS-31
On no FDA compounding list. Neither SS-31 nor elamipretide, the name it is studied under, appears in the 503A bulk drug substances categories (updated May 14, 2026) or the 503B categories (updated March 21, 2025).
DSIP
On no FDA compounding list. The name does not appear in the 503A bulk drug substances categories (updated May 14, 2026) or in the 503B categories (updated March 21, 2025).
Semax
On no FDA compounding list. Semax appears in neither the 503A bulk drug substances categories (updated May 14, 2026) nor the 503B categories (updated March 21, 2025).
Selank
On no FDA compounding list. Selank appears in neither the 503A bulk drug substances categories (updated May 14, 2026) nor the 503B categories (updated March 21, 2025).
Kisspeptin
Kisspeptin-10 is in 503A Category 2 (bulk drug substances that raise significant safety risks), placed there September 29, 2023 and still listed in the May 14, 2026 update. FDA cites a possible risk of immunogenicity and peptide-related impurities, and says it has no, or only limited, safety information for the proposed routes.
BPC-157
On no 503A list (removed from Category 2 in April 2026, never in Category 1). The FDA's compounding advisory committee voted 8–6 (one abstention) in July 2026 to favor listing it; the vote is a recommendation, not binding on the FDA, and pharmacies may not compound it until final rulemaking.
TB-500
On no FDA compounding list: absent from the 503A categories (updated May 14, 2026) and the 503B categories (updated March 21, 2025). FDA's compounding advisory committee voted 8-6 (one abstention) in July 2026 to favor listing it; the vote is a recommendation, not binding on the FDA, and pharmacies may not compound it until final rulemaking.
CJC-1295/ipamorelin
On no FDA compounding list. The name does not appear in the 503A bulk drug substances categories (updated May 14, 2026) or in the 503B categories (updated March 21, 2025), so neither a 503A pharmacy nor a 503B outsourcing facility has a listed route to it.
MOTS-c
On no 503A list (not in Categories 1–3 of the May 14, 2026 update). The FDA's compounding advisory committee voted 7–5 (two abstentions) in July 2026 to favor listing it; the vote is a recommendation, not binding on the FDA, and pharmacies may not compound it until final rulemaking.
Tesamorelin
Sold compounded at $200 for 24 mg. The FDA says compounded versions of this biologic do not qualify for the compounding exemptions.
GHK-Cu injection
The 503A list covers GHK-Cu only by routes other than injection, so only the scalp solution is set against other sellers.
Semaglutide and tirzepatide microdose
The same B12 vials, at $25 and $45, drawn at a smaller dose.
Methylene blue, ondansetron, vitamin and lipotropic injections
Not peptides, so outside what this site covers.

How it bills

You pay in two places. RxPepsDirect takes the $39 visit fee at checkout, once per order, for up to three different peptides. The pharmacy then charges the listed vial price plus $15 for FedEx overnight, and that $15 covers the whole order. A first sermorelin order therefore comes to $134. There is no membership and no prepaid plan. Automatic refills are optional: they start only if you opt in, and you can switch them off in your dashboard. Each automatic refill is still a $39 visit with a provider review. Cancel before a provider opens your intake and the $39 comes back. After that point it stays with RxPepsDirect, even when no prescription is written. Orders are final once submitted, and dispensed medication generally cannot be returned. The service is cash-pay only.

Availability: 28 states plus DC

For and against

  • For: Medical director and lead prescriber named, with NPI numbers
  • For: Dose and schedule printed on every product page
  • For: Sterility and endotoxin report published per batch
  • For: A single $39 fee covers three peptides per order
  • For: Optional live video visit with the medical director
  • Against: The compounding pharmacy is not named
  • Against: The $39 is kept once review starts, even if declined
  • Against: Every reorder is a new $39 visit plus $15 shipping
  • Against: Glutathione back-ordered with no restock date
  • Against: Prescribes in 28 states plus DC only
  • Against: Batch reports test sterility, not purity

The evidence behind what it sells

Right for

Someone who wants the prescriber's name, the dose and the batch test in view before paying, and is comfortable reordering vial by vial.

Look elsewhere if

Anyone outside the 28 states and DC it serves, or anyone who needs to know which pharmacy compounds the drug.

Other sellers for weight

RxPepsDirect

Frequently asked questions

Who writes the prescription at RxPepsDirect?
A nurse practitioner or physician assistant licensed in your state, under medical director Dr. Jonathan Snipes, MD. Kim Callender, FNP-BC, is named as lead prescriber, and both NPI numbers are listed on the About page.
Can I talk to a doctor before ordering?
Yes, for a fee. A 30-minute video visit with Dr. Snipes costs $149.99 and includes the $39 visit fee. Otherwise a provider reviews your questionnaire without a live call.
Does RxPepsDirect name its pharmacy?
No. The pages describe a licensed 503A compounding pharmacy in Texas with a sterile-compounding license, but give no name. Each batch's lab report is published by lot number.
Will RxPepsDirect charge me automatically?
Only if you opt in to automatic refills. Each refill is a $39 visit charged to your saved card and still reviewed by a provider. You can switch them off in your dashboard.

See what RxPepsDirect prescribes today

RxPepsDirect sets its own prices, plans and the states it serves. Check them before you start.

Visit RxPepsDirect →
Written by Leah Garner from RxPepsDirect’s own public pages, against the published methodology. No outcome is claimed first-hand and no score is given. A partnership never changes what this page says; see how the site is paid.